Inhibition of PI3K/mTOR Overcomes Nilotinib Resistance in BCR-ABL1 Positive Leukemia Cells through Translational Down-Regulation of MDM2

Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment

(2015) Alberto M. Martelli et al.   Oncotarget

BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance

(2013) W T Parker et al.   BRITISH JOURNAL OF CANCER

Comparing nilotinib with dasatinib as second-line therapies in patients with chronic myelogenous leukemia resistant or intolerant to imatinib – a retrospective chart review analysis

(2013) James D. Griffin et al.   CURRENT MEDICAL RESEARCH AND OPINION

Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study

(2012) F J Giles et al.   LEUKEMIA

Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors

(2012) F U Wöhrle et al.   LEUKEMIA

Mechanisms responsible for nilotinib resistance in human chronic myeloid leukemia cells and reversal of resistance

(2012) Aylin Camgoz et al.   LEUKEMIA & LYMPHOMA

GAB2--a Scaffolding Protein in Cancer

(2012) S. J. Adams et al.   MOLECULAR CANCER RESEARCH

The PI3K/PKB signaling module as key regulator of hematopoiesis: implications for therapeutic strategies in leukemia

(2011) R. Polak et al.   BLOOD

Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach in Human Ovarian Carcinoma

(2011) C. Santiskulvong et al.   CLINICAL CANCER RESEARCH

The immunohistochemical staining pattern of Gab2 correlates with distinct stages of chronic myeloid leukemia

(2011) Konrad Aumann et al.   HUMAN PATHOLOGY

BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance

(2011) Hilmar Quentmeier et al.   Journal of Hematology & Oncology

Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib

(2010) Paul W. Manley et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Activity of the Novel Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 against T-Cell Acute Lymphoblastic Leukemia

(2010) F. Chiarini et al.   CANCER RESEARCH

Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia

(2010) N. Chapuis et al.   CLINICAL CANCER RESEARCH

NVP-BEZ235 as a New Therapeutic Option for Sarcomas

(2010) M. C. Manara et al.   CLINICAL CANCER RESEARCH

The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor

(2010) J. J. Manfredi   GENES & DEVELOPMENT

Regulation of XIAP Translation and Induction by MDM2 following Irradiation

(2009) Lubing Gu et al.   CANCER CELL

MDM2 Antagonist Nutlin-3 Displays Antiproliferative and Proapoptotic Activity in Mantle Cell Lymphoma

(2009) Y. Tabe et al.   CLINICAL CANCER RESEARCH

SET-NUP214 fusion in acute myeloid leukemia- and T-cell acute lymphoblastic leukemia-derived cell lines

(2009) Hilmar Quentmeier et al.   Journal of Hematology & Oncology

Targeting Melanoma with Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors

(2009) R. Marone et al.   MOLECULAR CANCER RESEARCH

Cell cycle kinases as therapeutic targets for cancer

(2009) Silvia Lapenna et al.   NATURE REVIEWS DRUG DISCOVERY

Evidence that Resistance to Nilotinib May Be Due to BCR-ABL, Pgp, or Src Kinase Overexpression

(2008) F.-X. Mahon et al.   CANCER RESEARCH

MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2

(2008) L Gu et al.   LEUKEMIA

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

(2008) S.-M. Maira et al.   MOLECULAR CANCER THERAPEUTICS